Document Detail

Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development.
Jump to Full Text
MedLine Citation:
PMID:  17710236     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Understanding lung development has significant importance to public health because of the fact that interruptions in the normal developmental processes can have prominent effects on childhood and adult lung health. It is widely appreciated that the retinoic acid (RA) pathway plays an important role in lung development. Additionally, PPARs are believed to partner with receptors of this pathway and therefore could be considered extensions of retinoic acid function, including during lung development. This review will begin by introducing the relationship between the retinoic acid pathway and PPARs followed by an overview of lung development stages and regulation to conclude with details on PPARs and the retinoic acid pathway as they may relate to lung development.
Authors:
Dawn M Simon; Thomas J Mariani
Related Documents :
18312386 - Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors co...
3663136 - Terminal-group oxidation of retinol by mouse epidermis. inhibition in vitro and in vivo.
11600826 - Hiv-protease inhibitors alter retinoic acid synthesis.
15793506 - The effect of topical tretinoin on tissue strength and skin components in a murine inci...
109596 - A controlled trial of glucose versus glucose and amino acids in premature infants.
15528496 - Fatty acid production from amino acids and alpha-keto acids by brevibacterium linens bl2.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  PPAR research     Volume:  2007     ISSN:  1687-4757     ISO Abbreviation:  PPAR Res     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269101     Medline TA:  PPAR Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  91240     Citation Subset:  -    
Affiliation:
Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PPAR Res
Journal ID (publisher-id): PPAR
ISSN: 1687-4757
ISSN: 1687-4765
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2007 D. M. Simon and T. J. Mariani.
open-access: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received Day: 6 Month: 3 Year: 2007
Accepted Day: 9 Month: 5 Year: 2007
Print publication date: Year: 2007
Electronic publication date: Day: 27 Month: 6 Year: 2007
Volume: 2007E-location ID: 91240
ID: 1940052
PubMed Id: 17710236
DOI: 10.1155/2007/91240

Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development
Dawn M. Simon1*
Thomas J. Mariani2
1Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA 30322, USA
2Division of Pulmonary Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Correspondence: *Dawn M. Simon: dawn_simon@oz.ped.emory.edu
[other] Recommended by Theodore J. Standiford

1. THE RETINOIC ACID PATHWAY AND PPAR

The effects of retinoic acid are mediated by the retinoic acid receptors (RAR) and retinoid X receptors (or 9-cis retinoic acid receptor, RXR). RARs and RXRs each have 3 separate subtypes: α, β, and γ. RXR is specific for the 9-cis retinoic acid (9CRA) stereoisomer, while RAR binds both 9CRA and all-trans retinoic acid (ATRA). RARs form heterodimers with the three RXR subtypes and RXR's form heterodimers with members of the nuclear receptor family, including PPARγ. RXRs can also form homodimers, which among other effects, can activate PPAR target genes [1]. While as a group, the three PPAR isoforms (α, β/δ, and γ) function to regulate cellular lipid utilization and homeostasis, each isoform has discrete yet overlapping functions and ligand specificities. Upon activation by an appropriate ligand, PPARs form an obligate heterodimer with RXR to recruit nuclear receptor coactivators. Because they function as heterodimers with the RXR, PPARs could be considered an extension or modulator of the retinoic acid signaling pathway. The canonical pathway is that these ligand-activated PPAR-RXR heterodimers bind to peroxisome proliferator response elements (PPREs), and activate gene transcription, although PPARs can also serve as active transcriptional repressors [2]. Furthermore, nongenomic functions of PPARs upon gene regulation (e.g., regulatory effects independent of PPRE binding) have been reported [35]. For instance, PPARs are capable of trans-repression of other transcription factors, through direct interaction or through interaction with other coactivator/corepressors. Schupp and colleagues recently demonstrated that a RARα antagonist can directly affect PPARγ activity and therefore be considered both a PPARγ agonist and RARα antagonist [6]. Additionally, Szatmari and colleagues found that PPARγ regulates CD1d, a molecule involved in dendritic cell antigen presentation, by inducing retinoic acid synthesis through RARα [7]. These observations highlight the complex interplay between nuclear receptors. Given the numerous pathways through which PPARs could regulate gene expression either directly or indirectly, it is easy to envision that they may play a role in the complex regulatory mechanisms of lung development.


2. THE REGULATION OF MAMMALIAN LUNG DEVELOPMENT

Mammalian lung development follows a highly regulated, morphogenetic program beginning near mid-gestation and continuing through postnatal life [8, 9]. The mammalian lung initiates as an out-pouching of the ventral foregut endoderm. Initially, during the “embryonic” stage of organ development, which occurs during 5th and 6th week of gestation in the human or embryonic days 9.5 (E9.5) and E10.5 in the mouse, the lung arises as a ventral diverticulum of the foregut endoderm, separating from the esophagus and elongating caudally. This bud branches to give rise to the main bronchi of the left and right lung. Significant recent advances have been made in the understanding of the genetic and molecular mechanisms governing many of the early processes of lung development [10, 11]. Lung bud initiation and outgrowth is controlled by both the Gli/Shh pathway [1214] and FGF receptor signaling [15].

Beginning in the pseudoglandular stage (which occurs between 6 and 16 weeks of gestation in humans or E10.5–16.5 in mice) and continuing through the canalicular stage (which occurs between 16 and 26 weeks of gestation in humans or E16.5–17.5 in mice), this lung bud subsequently undergoes repeated rounds of dichotomous branching to produce the tree-like structure of the mature conducting airway. Numerous molecules are currently appreciated as playing a role in the branching process. Many, though certainly not all, of these molecules belong to the BMP and FGF signaling pathways [1621]. BMP-4 and FGF-10 are believed to form signaling centers that specify branch initiation sites and outgrowth [22]. Locations of branching specificity are limited, in part, by molecules such as Sprouty and Noggin, which antagonize FGF and BMP signaling [23, 24]. Many other factors such as EGF, Shh, and Wnt also play a role in the regulation of branching morphogenesis. The involvement of these particular pathways also highlights the role of epithelial-mesenchymal interactions in lung development. It is well accepted that epithelial-mesenchymal interactions are essential for normal lung development, primarily during embryonic growth and differentiation [25, 26]. The specific role of epithelial-mesenchymal interactions in later stages of lung development, including postnatal lung maturation, is unclear. In addition to the continuation of branching morphogenesis, the canalicular stage is marked proximo-distal cell type specification and vascularization.

From 26 to 36 weeks of gestation (E17.5 through postnatal day 4 in mice), the “saccular” stage completes formation of the conducting airway tree and differentiation of distal epithelial cells. During this stage, the distal architecture of the lung dramatically changes due to further differentiation and flattening of distal airway epithelia. This process is coordinated by factors such as GATA-6, Nkx2.1, HNF3β, C/EBPα, glucococorticoid hormones, and FGFs [27]. At or near the end of the saccular stage, the lung becomes prepared for a transition to air breathing with the production of pulmonary surfactant. Recent studies support a role for the forkhead box transcription factor, Foxa2 as a master regulator of surfactant production [28], in coordination with the transcription factors, Ttf1 and C/EBPα [29]. The calcineurin/NFAT signaling pathway also appears to play a role in this process [30].

Finally, the gas exchange portions of the lung are formed during the alveolar stage of development. This occurs beginning in week 36 of human gestation and continues through early childhood. In mice, this stage occurs entirely during the postnatal period, beginning in the first week of life and continuing through the first month. Maturation of gas-exchange capacity involves airway wall secondary crest septation and elongation, a process referred to as alveogenesis. Elongation of secondary septae results in partitioning of saccules into alveolar ducts and alveoli with an increase in gas-exchange surface area. Lung maturation and alveogenesis continues after birth in both rodents and humans. Although the number of airway generations and branching pattern of the lung is established at birth, the morphology of the lung parenchyma is quite different between the newborn and the adult [31]. Alveoli continue to form for at least 2 years after birth in humans. A detailed understanding of the regulatory processes controlling alveogenesis is lacking. Retinoic acid (discussed further below), PDGF, and FGF signaling all contribute to the regulation of secondary crest elongation. PDGF-A is essential in alveolar formation as defined by failed alveogenesis in its deficiency state secondary to a lack of development of alveolar myofibroblasts [32]. FGF signaling is also critical to alveogenesis, again, as defined by combined deficiency in FGFR3 and FGFR4 [33]. Interestingly, the ligand(s) mediating this effect is unknown. These data can be integrated into a model predicting morphogenic gradients of RA and FGF signaling secondary crest elongation [34]. In recent years, the importance of coordinated development of the vasculature during alveolarization has gained appreciation. It is clear that the appropriate balance of VEGF activity, which is an important pathway for vascular development and maintenance, plays a critical role in alveogenesis [3538]. VEGF also appears to play a critical role in promoting surfactant expression [39].

Boyden and Tompsett have described a mechanism for airspace formation distinct from the process of saccule subdivision by secondary septal elongation; the transformation of terminal or respiratory bronchioles into alveolar ducts [31, 40]. Massaro et al. corroborated this concept, finding that airspaces can develop through the nutritionally-dependent elongation of the conducting airway and de novo formation of alveoli (termed “retrograde alveolarization of bronchioles”) [41]. Since the time of these seminal observations, only a few studies have clarified the regulation of alveolar duct formation and its contribution to airspace structure. Intact collagen and/or elastin fibers appear necessary for the development of alveolar ducts, as treatment of neonatal rats with the BAPN, an inhibitor of the collagen and elastin cross-linking enzyme lysyl oxidase results in increased volume density of alveolar ducts [42]. Indomethacin treatment of neonatal rats also results in increased alveolar duct formation, implicating endogenous prostaglandin levels as a regulatory component in this process [43].


3. RETINOIC ACID SIGNALING IS ESSENTIAL AT MANY POINTS IN LUNG DEVELOPMENT

The retinoic acid pathway can have effects on all stages of lung development (see Figure 1). The RARs and RXRs have distinct expression patterns, notably during mouse embryonic development [4447]. Specifically, RXRs have been shown to be expressed in the human lung during critical periods in development from 13 weeks gestation until term, then their expression becomes markedly reduced in the adult [44]. Interestingly, retinoic acid signaling is downregulated during lung epithelial tubule branching and differentiation, which ultimately allows formation of mature type I and II cells [46, 48].

To understand their functional role, gene-targeted mice have been generated for all 3 RARs and RXRs [4951]. RAR single mutants are viable though they display a range of vitamin A deficiency syndromes, which increase when double null mutants are generated [49, 50]. RXRα loss results in fetal lethality at around E14.5 [52, 53]. Similar to PPARγ null mutants, these mice display severe myocardial hypoplasia. Because of the in utero lethality, mice with alleles for conditional gene targeting have been generated [51]. Based on these studies, RXRα has been found to be a crucial mediator of metabolism and skin development [5457]. RXRβ mutant fetuses also have high mortality (50%) with infertility in viable male pups [58]. RXRγ mutant mice survive and are fertile though they have abnormal metabolism secondary to alterations in pituitary-thyroid axis [59, 60]. The development of these genetically altered mice has provided insight into the functional role of the RA signaling pathway as it relates to lung development. Targeted deletion of RARβ alters the regulation of lung septation [61]. RARγ deletion also results in reduced elastic tissue and alveolar number with increase in mean chord length [62]. The authors found similar results with RXRα deletion. Desai and colleagues demonstrated that balanced activation of RARα and β is critical for normal lung bud initiation and endodermal differentiation [63]. Mollard and colleagues determined that RA signaling through RARβ during the pseudoglandular stage promotes the formation of conducting airways [64]. Because single RAR mutants have few to no lung abnormalities [61, 6468], double mutants have been developed because of the apparent redundancy in these receptors. For example, RARα/RXRα and RARα/β double mutants develop lung hypoplasia or agenesis [6971]. Additionally, retinoids are capable of promoting the formation of alveoli in neonatal rats and in adult rats with elastase-induced emphysema [72, 73].


4. EPITHELIAL CELL PPARγ EXPRESSION CONTRIBUTES TO THE REGULATION OF LUNG MATURATION

Most of the literature regarding the role of PPARs in the lung has focused on understanding PPARγ. While PPARα shares the common characteristic of having potent anti-inflammatory properties with PPARγ, it has not been shown to have a role in regulating lung development. Similarly, there has been no description for a role of PPARβ/δ in modulating lung development though Matsuura and colleagues demonstrated upregulation of PPARβ/δ expression in induced human tracheobronchial epithelial (HBE) cells which suggests that PPARβ/δ may have a role in the squamous differentiation process of airway cells [74]. PPARγ is expressed as at least 2 different isoforms, γ1 and γ2. These isoforms differ only by the addition of 30 amino acids at the amino terminus of γ2, and appear to be functionally equivalent. While PPARγ2 is expressed primarily in adipose tissue, PPARγ1 is expressed in a broad range of tissues including the lung, heart, skeletal muscle, large and small intestine, kidney, pancreas, spleen, and breast [5, 75]. Within the lung, PPARγ expression has been reported in the airway epithelium [76, 77], bronchial smooth muscle [76, 78], endothelial cells [79], macrophages [80], eosinophils [81], and dendritic cells [82]. There is little data describing the expression of PPARγ in the developing lung. Barlier-Mur and colleagues found that PPARγ1 mRNA was detectable at 18 days gestation in fetal rat lungs, as well as the C/EBPs [83]. The expression of these factors increased during development, peaking just prior to delivery. While they and others [84] have reported PPARγ expression in type II alveolar cells, they did not see that this expression pattern was developmentally regulated, although it could be induced by exposure of cultured type II alveolar cells to dexamethasone, retinoic acid, EGF, and KGF. Interestingly, PPARγ protein concentrations were only induced by KGF, and not with EGF or dexamethasone. We observed a spatial and temporally restricted pattern of PPARγ expression, including prominent immunolocalization within the conducting airway epithelium of normal mouse lungs [85]. This pattern of staining was first detectable at birth and increased in intensity over the first few weeks of life in mice.

PPARγ can play a prominent role in regulating cellular differentiation. PPARγ is sufficient and necessary to promote the formation of adipocytes and the development of adipose tissue in vivo [75, 86]. This appears to be due, at least in part, to the ability of PPARγ to regulate numerous genes involved in lipid metabolism. Complete germ-line PPARγ deficiency in mice results in embryonic death at mid gestation, prior to lung development due to failed placental cytotrophoblast differentiation, which is necessary for placental vascularization [87]. Recently, Duan and colleagues generated a mouse model of complete PPARγ deficiency that spared the trophoblast, allowing delivery of viable pups that they used to study the role of PPARγ in the metabolic syndrome [88]. Unfortunately, there was no description of effect on lung development. A role for PPARγ in promoting cellular differentiation is also suggested by its antitumor effects in vivo and in vitro, which include suppressing cellular proliferation, promoting cell death, and inducing differentiation of malignant tumors cells from various organs including the lung [89], breast [90], colon [91], and adipose tissue [92]. In isolated lung epithelial cells, PPARγ can promote the expression of markers for terminal differentiation including the expression of surfactant associated protein genes [9395].

In addition to its roles in cellular differentiation and organ/tissue development, PPARγ is widely appreciated as a regulator of tissue inflammation, which will be discussed in other sections of this review. In brief, PPARγ activation can modulate various immune cell functions. For example, PPARγ regulates monocyte/macrophage differentiation and promotes cellular activation as measured by increased production of metalloproteinases and reactive oxygen species [96]. Dendritic cells express PPARγ, which upon activation can influence cell maturation and antigenic peptide presentation to T cells [82, 97]. PPARγ is expressed at low levels in resting T cells, but is increased following T cell activation where PPARγ can then inhibit T cell IL-2 and IFNγ production [98]. Additionally, PPARγ activation has an antiproliferative and cytotoxic effect on normal and malignant B cells [99]. While PPARγ expression has been reported in these various cell types, the target cells and mechanisms for the protective, anti-inflammatory activities of PPARγ ligands within the lung are unclear. Some of these inflammation-related functions of PPARγ appear to mediate, at least in part, the regulation of resident cell functions. PPARγ has been shown to be expressed in cultured human airway smooth muscle cells and its activation inhibits cell growth while inducing apoptosis and inhibits release of GM-CSF and G-CSF to a greater extent than dexamethasone, a medication frequently used in asthma [78]. Further, in cultured human airway epithelial cells, PPARγ activation can inhibit expression of proinflammatory mediators such as TNF-α, IL-8, iNOS, and MCP-1 [5, 77, 81].

Our laboratory sought to understand the physiological role of epithelial cell PPARγ and its potential contribution to lung development and homeostasis, considering the fact that PPARγ is capable of having a significant and complex influence upon cellular differentiation, organ development, and the control of tissue homeostasis. We hypothesized that epithelial cell PPARγ might be necessary for the establishment and maintenance of normal lung structure through regulation of epithelial cell differentiation and/or control of lung inflammation.

Using a conditional targeting strategy, we deleted the PPARγ gene specifically within conducting airway epithelial cells [85]. We started by generating a new line of Cre Recombinase-expressing targeting mice, termed CCtCre, where the rat CC10 promoter was used to drive Cre expression specifically within the lung conducting airway epithelium. Functional targeting specificity in these CCtCre mice was confirmed by crossing them to the ROSA26 reporter line. Crossing the CCtCre mice with mice engineered to have loxP sites (targets of Cre-mediated recombination) flanking exon 2 of the PPARγ gene led to targeted deletion within the airway epithelium (see Figure 2).

Lungs from PPARγ conditionally targeted, airway epithelial cell PPARγ deficient mice revealed structural and functional abnormalities at maturity, but not prior to maturity, including enlarged airspaces consistent with a deficiency in postnatal lung maturation (see Figure 1). Abnormal airspace structure persists throughout adulthood, but is not progressive and occurs in the absence of inflammation. While control animals show a reduction in mean airspace size between 2 and 8 weeks of age, conditionally targeted, airway epithelial cell PPARγ deficient animals do not. These data suggest that the phenotype results from an insufficiency in postnatal lung maturation. This does not appear to be the result of a defect in alveogenesis, as numerous normal-sized alveoli exist in conditionally targeted lungs. However, an abnormal distribution of airspaces, with increased numbers of alveolar ducts is observed (unpublished observations).

No qualitative or quantitative changes in the major classes of airway and airspace epithelial cells are evident, but some characteristics of airway epithelial cell differentiation appear affected. We found, through genome wide expression analysis of targeted airway epithelial cells, changes consistent with alterations in PPARγ function (Lip1, Abca1, and Apoe) and cellular differentiation (Moesin, Ctsb, Klf13). We believe that altered epithelial-mesenchymal interactions, secondary to epithelial PPARγ deficiency, lead to changes in extracellular matrix gene expression and abnormal lung structure at maturity. Efforts to further define the mechanism(s) mediating this abnormality and to test the role of this transcription factor in regulating airway inflammation are the focus of current investigation.

In summary, it is well appreciated that the retinoic acid signaling pathway contributes to the regulation of lung development at many different stages, including during terminal maturation giving rise to the functional gas exchange units of the lung, the alveoli. Although retinoic acid activity during alveogenesis appears to be linked to elastin fiber formation, the cellular and molecular mechanisms for these effects are not well defined. It has recently become apparent that PPARγ has a role in contributing to these regulatory processes. Again, the mechanisms at work are yet to be defined. Potentially, they involve the regulation of epithelial cell differentiation, and may act in part through interaction with the RARs and RXRs. Tremendous current activities in the field of PPAR biology should rapidly lead to a better understanding of the role of these transcription factors in promoting lung maturation and their potential contribution to human lung disease.


References
1. Ijpenberg A,Tan NS,Gelman L,et al. In vivo activation of PPAR target genes by RXR homodimersThe EMBO Journal 2004;23(10):2083–2091. [pmid: 15103326]
2. Yu C,Markan K,Temple KA,Deplewski D,Brady MJ,Cohen RN. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor γ transcriptional activity and repress 3T3-L1 adipogenesisJournal of Biological Chemistry 2005;280(14):13600–13605. [pmid: 15691842]
3. Wang LH,Yang XY,Zhang X,et al. Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cellsImmunity 2004;20(2):205–218. [pmid: 14975242]
4. Gurnell M,Wentworth JM,Agostini M,et al. A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesisJournal of Biological Chemistry 2000;275(8):5754–5759. [pmid: 10681562]
5. Daynes RA,Jones DC. Emerging roles of PPARs in inflammation and immunityNature Reviews Immunology 2002;2(10):748–759. [pmid: 12360213]
6. Schupp M,Curtin JC,Kim RJ,Billin AN,Lazar MA. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activityMolecular Pharmacology 2007;71:1251–1257. [pmid: 17290005]
7. Szatmari I,Pap A,Rühl R,et al. PPARγ controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cellsJournal of Experimental Medicine 2006;203(10):2351–2362. [pmid: 16982809]
8. Mariani TJ,Kaminski N. Gene expression studies in lung development and lung stem cell biologyCurrent Topics in Developmental Biology 2004;64:57–71. [pmid: 15563944]
9. Mariani TJ,Reed JJ,Shapiro SD. Expression profiling of the developing mouse lung: insights into the establishment of the extracellular matrixAmerican Journal of Respiratory Cell and Molecular Biology 2002;26(5):541–548. [pmid: 11970905]
10. Warburton D,Zhao J,Berberich MA,Bernfield M. Molecular embryology of the lung: then, now, and in the futureAmerican Journal of Physiology - Lung Cellular and Molecular Physiology 1999;276(5, part 1):L697–L704.
11. Warburton D,Schwarz M,Tefft D,Flores-Delgado G,Anderson KD,Cardoso WV. The molecular basis of lung morphogenesisMechanisms of Development 2000;92(1):55–81. [pmid: 10704888]
12. Motoyama J,Liu J,Mo R,Ding Q,Post M,Hui C-C. Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagusNature Genetics 1998;20(1):54–57. [pmid: 9731531]
13. Litingtung Y,Lei L,Westphal H,Chiang C. Sonic hedgehog is essential to foregut developmentNature Genetics 1998;20(1):58–61. [pmid: 9731532]
14. Pepicelli CV,Lewis PM,McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lungCurrent Biology 1998;8(19):1083–1086. [pmid: 9768363]
15. Peters K,Werner S,Liao X,Wert S,Whitsett JA,Williams L. Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lungThe EMBO Journal 1994;13(14):3296–3301. [pmid: 8045260]
16. Bellusci S,Grindley J,Emoto H,Itoh N,Hogan BLM. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lungDevelopment 1997;124(23):4867–4878. [pmid: 9428423]
17. Sutherland D,Samakovlis C,Krasnow MA. branchless encodes a Drosophila FGF homolog that controls tracheal cell migration and the pattern of branchingCell 1996;87(6):1091–1101. [pmid: 8978613]
18. Park WY,Miranda B,Lebeche D,Hashimoto G,Cardoso WV. FGF-10 is a chemotactic factor for distal epithelial buds during lung developmentDevelopmental Biology 1998;201(2):125–134. [pmid: 9740653]
19. Min H,Danilenko DM,Scully SA,et al. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchlessGenes and Development 1998;12(20):3156–3161. [pmid: 9784490]
20. Sekine K,Ohuchi H,Fujiwara M,et al. Fgf10 is essential for limb and lung formationNature Genetics 1999;21(1):138–141. [pmid: 9916808]
21. Bellusci S,Henderson R,Winnier G,Oikawa T,Hogan BLM. Evidence from normal expression and targeted misexpression that bone morphogenetic protein-4 (Bmp-4) plays a role in mouse embryonic lung morphogenesisDevelopment 1996;122(6):1693–1702. [pmid: 8674409]
22. Weaver M,Dunn NR,Hogan BLM. Bmp4 and Fgf10 play opposing roles during lung bud morphogenesisDevelopment 2000;127(12):2695–2704. [pmid: 10821767]
23. Tefft JD,Matt L,Smith S,et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesisCurrent Biology 1999;9(4):219–222. [pmid: 10074434]
24. Weaver M,Yingling JM,Dunn NR,Bellusci S,Hogan BLM. Bmp signaling regulates proximal-distal differentiation of endoderm in mouse lung developmentDevelopment 1999;126(18):4005–4015. [pmid: 10457010]
25. Roth-Kleiner M,Post M. Genetic control of lung developmentBiology of the Neonate 2003;84(1):83–88. [pmid: 12890942]
26. Shannon JM,Hyatt BA. Epithelial-mesenchymal interactions in the developing lungAnnual Review of Physiology 2004;66:625–645.
27. Cardoso WV. Lung morphogenesis revisited: old facts, current ideasDevelopmental Dynamics 2000;219(2):121–130. [pmid: 11002333]
28. Wan H,Xu Y,Ikegami M,et al. Foxa2 is required for transition to air breathing at birthProceedings of the National Academy of Sciences of the United States of America 2004;101(40):14449–14454. [pmid: 15452354]
29. Martis PC,Whitsett JA,Xu Y,Perl A-KT,Wan H,Ikegami M. C/EBPα is required for lung maturation at birthDevelopment 2006;133(6):1155–1164. [pmid: 16467360]
30. Davé V,Childs T,Xu Y,et al. Calcineurin/Nfat signaling is required for perinatal lung maturation and functionJournal of Clinical Investigation 2006;116(10):2597–2609. [pmid: 16998587]
31. Burri PH. Fetal and postnatal development of the lungAnnual Review of Physiology 1984;46:617–628.
32. Boström H,Willetts K,Pekny M,et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesisCell 1996;85(6):863–873. [pmid: 8681381]
33. Weinstein M,Xu X,Ohyama K,Deng C-X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lungDevelopment 1998;125(18):3615–3623. [pmid: 9716527]
34. Mariani TJ. Regulation of alveogenesis by reciprocal proximodistal FGF and retinoic acid signalingAmerican Journal of Respiratory Cell and Molecular Biology 2004;31(2):S52–S57.
35. Kasahara Y,Tuder RM,Taraseviciene-Stewart L,et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysemaJournal of Clinical Investigation 2000;106(11):1311–1319. [pmid: 11104784]
36. Zeng X,Wert SE,Federici R,Peters KG,Whitsett JA. VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivoDevelopmental Dynamics 1998;211(3):215–227. [pmid: 9520109]
37. Gerber H-P,Hillan KJ,Ryan AM,et al. VEGF is required for growth and survival in neonatal miceDevelopment 1999;126(6):1149–1159. [pmid: 10021335]
38. Thébaud B,Ladha F,Michelakis ED,et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarizationCirculation 2005;112(16):2477–2486. [pmid: 16230500]
39. Compernolle V,Brusselmans K,Acker T,et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature miceNature Medicine 2002;8(7):702–710. [pmid: 12053176]
40. Boyden EA,Tompsett DH. The changing patterns in the developing lungs of infantsActa Anatomica 1965;61(2):164–192. [pmid: 5841161]
41. Massaro D,Teich N,Maxwell S,Massaro GD,Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in ratsJournal of Clinical Investigation 1985;76(4):1297–1305. [pmid: 4056033]
42. Kida K,Thurlbeck WM. The effects of β-aminopropionitrile on the growing rat lungAmerican Journal of Pathology 1980;101(3):693–710. [pmid: 7446713]
43. Nagai A,Katayama M,Thurlbeck WM,Matsui R,Yasui S,Konno K. Effect of indomethacin on lung development in postnatal rats: possible role of prostaglandin in alveolar formationAmerican Journal of Physiology - Lung Cellular and Molecular Physiology 1995;268(1, part 1):L56–L62.
44. Kimura Y,Suzuki T,Kaneko C,et al. Retinoid receptors in the developing human lungClinical Science 2002;103(6):613–621. [pmid: 12444914]
45. Dolle P,Fraulob V,Kastner P,Chambon P. Developmental expression of murine retinoid X receptor (RXR) genesMechanisms of Development 1994;45(2):91–104. [pmid: 8199055]
46. Malpel S,Mendelsohn C,Cardoso WV. Regulation of retinoic acid signaling during lung morphogenesisDevelopment 2000;127(14):3057–3067. [pmid: 10862743]
47. Dolle P,Ruberte E,Leroy P,Morriss-Kay G,Chambon P. Retinoic acid receptors and cellular retinoid binding proteins—I: a systematic study of their differential pattern of transcription during mouse organogenesisDevelopment 1990;110(4):1133–1151. [pmid: 1966045]
48. Wongtrakool C,Malpel S,Gorenstein J. Down-regulation of retinoic acid receptor α signaling is required for sacculation and type I cell formation in the developing lungJournal of Biological Chemistry 2003;278(47):46911–46918. [pmid: 12947094]
49. Mark M,Ghyselinck NB,Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesisAnnual Review of Pharmacology and Toxicology 2006;46:451–480.
50. Germain P,Chambon P,Eichele G,et al. International union of pharmacology. LX. Retinoic acid receptorsPharmacological Reviews 2006;58(4):712–725. [pmid: 17132850]
51. Germain P,Chambon P,Eichele G,et al. International union of pharmacology. LXIII. Retinoid X receptorsPharmacological Reviews 2006;58(4):760–772. [pmid: 17132853]
52. Kastner P,Grondona JM,Mark M,et al. Genetic analysis of RXRα developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesisCell 1994;78(6):987–1003. [pmid: 7923367]
53. Sucov HM,Dyson E,Gumeringer CL,Price J,Chien KR,Evans RM. RXR α mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesisGenes and Development 1994;8(9):1007–1018. [pmid: 7926783]
54. Li M,Chiba H,Warot X,et al. RXRα ablation in skin keratinocytes results in alopecia and epidermal alterationsDevelopment 2001;128(5):675–688. [pmid: 11171393]
55. Li M,Indra AK,Warot X,et al. Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermisNature 2000;407(6804):633–636. [pmid: 11034212]
56. Metzger D,Li M,Chambon P. Targeted somatic mutagenesis in the mouse epidermisMethods in Molecular Biology 2005;289:329–340. [pmid: 15502196]
57. Wan Y-JY,An D,Cai Y,et al. Hepatocyte-specific mutation establishes retinoid X receptor α as a heterodimeric integrator of multiple physiological processes in the liverMolecular and Cellular Biology 2000;20(12):4436–4444. [pmid: 10825207]
58. Kastner P,Mark M,Leid M,et al. Abnormal spermatogenesis in RXRβ mutant miceGenes and Development 1996;10(1):80–92. [pmid: 8557197]
59. Krezel W,Dupé V,Mark M,Dierich A,Kastner P,Chambon P. RXR γ null mice are apparently normal and compound RXR α+/−/RXR β−/−/RXR γ−/− mutant mice are viableProceedings of the National Academy of Sciences of the United States of America 1996;93(17):9010–9014. [pmid: 8799145]
60. Brown NS,Smart A,Sharma V,et al. Thyroid hormone resistance and increased metabolic rate in the RXR-γ- deficient mouseJournal of Clinical Investigation 2000;106(1):73–79. [pmid: 10880050]
61. Massaro GD,Massaro D,Chan WY,et al. Retinoic acid receptor-β: an endogenous inhibitor of the perinatal formation of pulmonary alveoliPhysiological Genomics 2000;4(1):51–57. [pmid: 11074013]
62. McGowan S,Jackson SK,Jenkins-Moore M,Dai H-H,Chambon P,Snyder JM. Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and alveolar numbersAmerican Journal of Respiratory Cell and Molecular Biology 2000;23(2):162–167. [pmid: 10919981]
63. Desai TJ,Chen F,Lü J,et al. Distinct roles for retinoic acid receptors α and β in early lung morphogenesisDevelopmental Biology 2006;291(1):12–24. [pmid: 16427040]
64. Mollard R,Ghyselinck NB,Wendling O,Chambon P,Mark M. Stage-dependent responses of the developing lung to retinoic acid signalingInternational Journal of Developmental Biology 2000;44(5):457–462. [pmid: 11032179]
65. Lohnes D,Kastner P,Dierich A,Mark M,LeMeur M,Chambon P. Function of retinoic acid receptor γ in the mouseCell 1993;73(4):643–658. [pmid: 8388780]
66. Ruberte E,Dolle P,Krust A,Zelent A,Morriss-Kay G,Chambon P. Specific spatial and temporal distribution of retinoic acid receptor γ transcripts during mouse embryogenesisDevelopment 1990;108(2):213–222. [pmid: 2161730]
67. Luo J,Pasceri P,Conlon RA,Rossant J,Giguere V. Mice lacking all isoforms of retinoic acid receptor β develop normally and are susceptible to the teratogenic effects of retinoic acidMechanisms of Development 1995;53(1):61–71. [pmid: 8555112]
68. Ghyselinck NB,Dupé V,Dierich A. Role of the retinoic acid receptor β (RARβ) during mouse developmentInternational Journal of Developmental Biology 1997;41(3):425–447. [pmid: 9240560]
69. Mendelsohn C,Lohnes D,Decimo D,et al. Function of the retinoic acid receptors (RARs) during development (II). multiple abnormalities at various stages of organogenesis in RAR double mutantsDevelopment 1994;120(10):2749–2771. [pmid: 7607068]
70. Kastner P,Mark M,Ghyselinck N,et al. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse developmentDevelopment 1997;124(2):313–326. [pmid: 9053308]
71. Maden M. The role of retinoic acid in embryonic and post-embryonic developmentProceedings of the Nutrition Society 2000;59(1):65–73. [pmid: 10828175]
72. Massaro GD,Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in ratsAmerican Journal of Physiology - Lung Cellular and Molecular Physiology 1996;270(2, part 1):L305–L310.
73. Massaro GC,Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in ratsNature Medicine 1997;3(6):675–677. [pmid: 9176496]
74. Matsuura H,Adachi H,Smart RC,Xu X,Arata J,Jetten AM. Correlation between expression of peroxisome proliferator-activated receptor β and squamous differentiation in epidermal and tracheobronchial epithelial cellsMolecular and Cellular Endocrinology 1999;147(1-2):85–92. [pmid: 10195695]
75. Berger J,Moller DE. The mechanisms of action of PPARsAnnual Review of Medicine 2002;53:409–435.
76. Benayoun L,Letuve S,Druilhe A,et al. Regulation of peroxisome proliferator-activated receptor γ expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodelingAmerican Journal of Respiratory and Critical Care Medicine 2001;164(8, part 1):1487–1494. [pmid: 11704601]
77. Wang AC,Dai X,Luu B,Conrad DJ. Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activationAmerican Journal of Respiratory Cell Molecular Biology 2001;24(6):688–693.
78. Patel HJ,Belvisi MG,Bishop-Bailey D,Yacoub MH,Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapyJournal of Immunology 2003;170(5):2663–2669.
79. Calnek DS,Mazzella L,Roser S,Roman J,Hart CM. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cellsArteriosclerosis, Thrombosis, and Vascular Biology 2003;23(1):52–57.
80. Chinetti G,Griglio S,Antonucci M,et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophagesJournal of Biological Chemistry 1998;273(40):25573–25580. [pmid: 9748221]
81. Woerly G,Honda K,Loyens M,et al. Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activationJournal of Experimental Medicine 2003;198(3):411–421. [pmid: 12900517]
82. Gosset P,Charbonnier A-S,Delerive P,et al. Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cellsEuropean Journal of Immunology 2001;31(10):2857–2865. [pmid: 11592060]
83. Barlier-Mur A-M,Chailley-Heu B,Pinteur C,Henrion-Caude A,Delacourt C,Bourbon JR. Maturational factors modulate transcription factors CCAAT/enhancer-binding proteins α, β, δ, and peroxisome proliferator-activated receptor-γ in fetal rat lung epithelial cellsAmerican Journal of Respiratory Cell and Molecular Biology 2003;29(5):620–626. [pmid: 14568882]
84. Michael LF,Lazar MA,Mendelson CR. Peroxisome proliferator-activated receptor γ1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytesEndocrinology 1997;138(9):3695–3703. [pmid: 9275054]
85. Simon DM,Arikan MC,Srisuma S,et al. Epithelial cell PPARγ contributes to normal lung maturationFASEB j 2006;20(9):1507–1509. [pmid: 16720732]
86. Zhang J,Fu M,Cui T,et al. Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivityProceedings of the National Academy of Sciences of the United States of America 2004;101(29):10703–10708. [pmid: 15249658]
87. Barak Y,Nelson MC,Ong ES,et al. PPARγ is required for placental, cardiac, and adipose tissue developmentMolecular Cell 1999;4(4):585–595. [pmid: 10549290]
88. Duan SZ,Ivashchenko CY,Whitesall SE,et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethalityJournal of Clinical Investigation 2007;117(3):812–822. [pmid: 17304352]
89. Shankaranarayanan P,Nigam S. IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor γ transcription factorJournal of Immunology 2003;170(2):887–894.
90. Mueller E,Sarraf P,Tontonoz P,et al. Terminal differentiation of human breast cancer through PPARγMolecular Cell 1998;1(3):465–470. [pmid: 9660931]
91. Sarraf P,Mueller E,Jones D,et al. Differentiation and reversal of malignant changes in colon cancer through PPARγNature Medicine 1998;4(9):1046–1052. [pmid: 9734398]
92. Tontonoz P,Singer S,Forman BM,et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptorProceedings of the National Academy of Sciences of the United States of America 1997;94(1):237–241. [pmid: 8990192]
93. Bren-Mattison Y,van Putten V,Chan D,Winn R,Geraci MW,Nemenoff RA. Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)Oncogene 2005;24(8):1412–1422. [pmid: 15608671]
94. Chang T-H,Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancerCancer Research 2000;60(4):1129–1138. [pmid: 10706135]
95. Yang L,Yan D,Yan C,Du H. Peroxisome proliferator-activated receptor γ and ligands inhibit surfactant protein B gene expression in the lungJournal of Biological Chemistry 2003;278:36841–36847. [pmid: 12829715]
96. Ricote M,Li AC,Willson TM,Kelly CJ,Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activationNature 1998;391(6662):79–82. [pmid: 9422508]
97. Hammad H,de Heer HJ,Soullié T,et al. Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthmaAmerican Journal of Pathology 2004;164(1):263–271. [pmid: 14695339]
98. Clark RB,Bishop-Bailey D,Estrada-Hernandez T,Hla T,Puddington L,Padula SJ. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responsesJournal of Immunology 2000;164(3):1364–1371.
99. Padilla J,Kaur K,Harris SG,Phipps RP. PPAR-γ-mediated regulation of normal and malignant B lineage cellsAnnals of the New York Academy of Sciences 2000;905:97–109. [pmid: 10818446]
100. Akiyama TE,Sakai S,Lambert G,et al. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol effluxMolecular and Cellular Biology 2002;22(8):2607–2619. [pmid: 11909955]

Article Categories:
  • Review Article


Previous Document:  The Role of PPARs in Lung Fibrosis.
Next Document:  The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and S...